Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus

OBJECTIVES: Numerous case reports have referred to new onset or flare of SLE after SARS-CoV-2 messenger RNA (mRNA) vaccines. Several observational studies showed that the short-term flare rate of SLE after SARS-CoV-2 vaccination is low. However, well-controlled clinical surveys are unavailable and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshida, Tsuneyasu, Tsuji, Hideaki, Onishi, Akira, Takase, Yudai, Shirakashi, Mirei, Onizawa, Hideo, Hiwa, Ryosuke, Kitagori, Koji, Akizuki, Shuji, Nakashima, Ran, Tanaka, Masao, Yoshifuji, Hajime, Morinobu, Akio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Epidemiology and Outcomes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9378947/
https://www.ncbi.nlm.nih.gov/pubmed/35961691
http://dx.doi.org/10.1136/lupus-2022-000727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9378947/
https://www.ncbi.nlm.nih.gov/pubmed/35961691
http://dx.doi.org/10.1136/lupus-2022-000727

Ejemplares similares